PMID- 28372906 OWN - NLM STAT- MEDLINE DCOM- 20180730 LR - 20201220 IS - 1573-2509 (Electronic) IS - 0920-9964 (Print) IS - 0920-9964 (Linking) VI - 190 DP - 2017 Dec TI - Comorbid diagnoses for youth at clinical high risk of psychosis. PG - 90-95 LID - S0920-9964(17)30183-4 [pii] LID - 10.1016/j.schres.2017.03.043 [doi] AB - Several studies have demonstrated that youth at clinical high risk (CHR) of developing psychosis have a high prevalence of comorbid psychiatric disorders. Less is known about the impact of comorbid diagnoses on later conversion to psychosis and the change over time. The aim of this study was to determine the frequency and distribution of psychiatric diagnoses at baseline and over time in the North American Prodrome Longitudinal Study (NAPLS 2) and the role of comorbid diagnoses in conversion to psychosis. The NAPLS 2 sample consisted of 744 CHR youth and 276 healthy controls. Only 21% of the CHR group did not have a comorbid diagnosis with many have 2-3 DSM-IV comorbid diagnoses. The most common diagnoses were anxiety and depressive disorders, which did improve over time. The only diagnosis at baseline that differentiated the converters from the non-converters was cannabis misuse. Comorbidity, except for cannabis use, was essentially independent of clinical outcome. It is possible that those with comorbid diagnoses are preferentially the help-seeking individuals that present for help in our clinics and research projects and that those who are at risk but do not have a comorbid diagnosis may not be seeking help in the prodromal phase. CI - Copyright (c) 2017 Elsevier B.V. All rights reserved. FAU - Addington, Jean AU - Addington J AD - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. Electronic address: jmadding@ucalgary.ca. FAU - Piskulic, Danijela AU - Piskulic D AD - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. FAU - Liu, Lu AU - Liu L AD - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. FAU - Lockwood, Jonathan AU - Lockwood J AD - Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. FAU - Cadenhead, Kristin S AU - Cadenhead KS AD - Department of Psychiatry, University of California San Diego, La Jolla, CA, United States. FAU - Cannon, Tyrone D AU - Cannon TD AD - Department of Psychology, Yale University, New Haven, CT, United States. FAU - Cornblatt, Barbara A AU - Cornblatt BA AD - Department of Psychiatry, Zucker Hillside Hospital, Queens, NY, United States. FAU - McGlashan, Thomas H AU - McGlashan TH AD - Department of Psychiatry, Yale University, New Haven, CT, United States. FAU - Perkins, Diana O AU - Perkins DO AD - Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States. FAU - Seidman, Larry J AU - Seidman LJ AD - Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, MA, United States. FAU - Tsuang, Ming T AU - Tsuang MT AD - Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Institute of Genomic Medicine, University of California, La Jolla, CA, United States. FAU - Walker, Elaine F AU - Walker EF AD - Department of Psychology, Emory University, Atlanta, GA, United States. FAU - Bearden, Carrie E AU - Bearden CE AD - Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Mathalon, Daniel H AU - Mathalon DH AD - Department of Psychiatry, University of California, San Francisco, San Francisco, United States; Psychiatry Service, San Francisco, CA, United States. FAU - Woods, Scott W AU - Woods SW AD - Department of Psychiatry, Yale University, New Haven, CT, United States. LA - eng GR - U01 MH082022/MH/NIMH NIH HHS/United States GR - U01 MH081984/MH/NIMH NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - U01 MH081902/MH/NIMH NIH HHS/United States GR - P50 MH080272/MH/NIMH NIH HHS/United States GR - U01 MH081988/MH/NIMH NIH HHS/United States GR - P50 MH066286/MH/NIMH NIH HHS/United States GR - U01 MH076989/MH/NIMH NIH HHS/United States GR - K24 MH076191/MH/NIMH NIH HHS/United States GR - R01 MH060720/MH/NIMH NIH HHS/United States GR - U01 MH081928/MH/NIMH NIH HHS/United States GR - U01 MH081857/MH/NIMH NIH HHS/United States GR - U01 MH082004/MH/NIMH NIH HHS/United States GR - U01 MH081944/MH/NIMH NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20170331 PL - Netherlands TA - Schizophr Res JT - Schizophrenia research JID - 8804207 SB - IM MH - Adolescent MH - Comorbidity MH - Disease Progression MH - Female MH - Humans MH - Interview, Psychological MH - Male MH - Marijuana Abuse/complications/diagnosis/epidemiology MH - Patient Acceptance of Health Care MH - Prodromal Symptoms MH - Psychotic Disorders/*complications/diagnosis/*epidemiology/therapy MH - Risk MH - Superior Sagittal Sinus MH - Young Adult PMC - PMC5731830 MID - NIHMS864908 OTO - NOTNLM OT - Anxiety OT - Clinical high risk OT - Comorbidity OT - DSM-IV diagnoses OT - Depression COIS- Author Conflicts of Interest Dr. Cannon reports that he is a consultant to the Los Angeles County Department of Mental Health and to Boehringer Ingelheim Pharmaceuticals. Dr. Woods reports that since 2005 he has received investigator-initiated research funding support from UCB Pharma, Glytech, Lilly, Bristol-Myers Squibb, and Pfizer. He has received sponsor-initiated research funding support from Kali-Duphar, Zeneca, Sandoz, Janssen, Auspex, and Teva and has consulted to Otsuka, Schering-Plough, Merck, Biomedisyn (unpaid), and Boehringer-Ingelheim and has received grants from NIMH, NARSAD, and the Donaghue Foundation. He has also served as an unpaid consultant to DSM-5. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists, is an inventor on a patent pending for a method of predicting psychosis risk using blood biomarker analysis, and has received royalties from Oxford University Press. All other authors report no conflicts. EDAT- 2017/04/05 06:00 MHDA- 2018/07/31 06:00 PMCR- 2018/12/01 CRDT- 2017/04/05 06:00 PHST- 2016/12/20 00:00 [received] PHST- 2017/03/21 00:00 [revised] PHST- 2017/03/23 00:00 [accepted] PHST- 2017/04/05 06:00 [pubmed] PHST- 2018/07/31 06:00 [medline] PHST- 2017/04/05 06:00 [entrez] PHST- 2018/12/01 00:00 [pmc-release] AID - S0920-9964(17)30183-4 [pii] AID - 10.1016/j.schres.2017.03.043 [doi] PST - ppublish SO - Schizophr Res. 2017 Dec;190:90-95. doi: 10.1016/j.schres.2017.03.043. Epub 2017 Mar 31.